© Business Wire 2009

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has dosed its first patient in a Phase 1 IND trial of CLT-008 for haematological malignancies. CLT-008 is an off-the-shelf cell-based biologic designed to rapidly produce mature neutrophils...